Literature DB >> 22717589

Atrial fibrillation, blood loss, and transfusion in patients with left ventricular dysfunction: what is the effect of cardiopulmonary bypass?

Omar A Jarral1, Srdjan Saso, Leanne Harling, Roberto Casula, Thanos Athanasiou.   

Abstract

Despite advancements in surgical technique, intensive care methods and pharmaceutical prophylaxis atrial fibrillation (AF) after on-pump coronary artery bypass remains common. Transfusion, blood loss, and cardiopulmonary bypass (CPB) have been identified as risk factors for AF and adverse outcomes such as early mortality. This study examines outcomes in patients with left ventricular dysfunction after revascularization with and without CPB. A systematic literature review identified 22 studies including 7,454 patients. Meta-analysis through subgroup analysis of the highest-quality studies revealed that the off-pump coronary artery bypass (OPCAB) technique is associated with a significantly lower incidence of blood loss, transfusion requirement, reoperation for bleeding, and length of stay. There was also a reduction in the incidence of AF in the OPCAB group but this was not statistically significant (odds ratio = 0.77, 95% confidence interval 0.58-1.02, p = 0.07). The results strengthen research suggesting that CPB has a damaging effect on hemostasis and subsequent transfusion requirements in this patient group. More research is required to assess the association between OPCAB and AF in patients with ventricular dysfunction.

Entities:  

Mesh:

Year:  2012        PMID: 22717589     DOI: 10.1097/MAT.0b013e31825cb055

Source DB:  PubMed          Journal:  ASAIO J        ISSN: 1058-2916            Impact factor:   2.872


  2 in total

Review 1.  Off-pump coronary artery bypass grafting in India.

Authors:  Kamales Kumar Saha
Journal:  Indian Heart J       Date:  2014-03-04

2.  Which aortic clamp strategy is better to reduce postoperative stroke and death: Single center report and a meta-analysis.

Authors:  Liyu Chen; Xiumeng Hua; Jiangping Song; Liqing Wang
Journal:  Medicine (Baltimore)       Date:  2018-03       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.